No. 19-3, Sanchong Road
9th Floor-2 Nangang District
Taipei 115
Taiwan
886 2 7750 0188
https://www.foreseepharma.com
版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工:
名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
---|---|---|---|---|
Dr. Benjamin Chien | Founder, CEO & Chairman | 16.17M | 無 | 無 |
Dr. Yuhua Li Ph.D. | Co-founder & Chief Technology Officer | 3.06M | 無 | 無 |
Dr. Mathieu Boudreau Ph.D. | Chief Business Officer & Chief Operating Officer | 585k | 無 | 無 |
Dr. Wenjin Yang Ph.D. | Chief Scientific Officer, Co-Acting Head of Clinical Development & VP | 4.99M | 無 | 無 |
Dr. Yisheng Lee Ph.D. | Chief Medical Officer, Acting Head of Clinical Development & Representative Director | 1.99M | 無 | 無 |
Dr. Jagdish Parasrampuria Ph.D. | Senior Vice President of Pharmaceutics and Manufacturing | 5.46M | 無 | 無 |
Mr. MengKung Chan | Chief Financial Officer | 無 | 無 | 1967 |
Liang Chris | Accounting Officer | 無 | 無 | 無 |
Dr. John Mao | Consultant | 無 | 無 | 無 |
Ms. Peifen Chou | Consultant | 無 | 無 | 1968 |
Foresee Pharmaceuticals Co., Ltd., a clinical-stage pharmaceutical company, engages in the development and commercialization of drugs in the United States, China, and Europe. The company's stabilized injectable formulation pipeline includes FP-001, which completed Phase III clinical study for the treatment of advanced stage prostate cancer; FP-004 that is in preclinical stage to treat opioids use disorder; FP-011 and FP-014, a long-acting sustained release dosage form for the treatment of breast cancer/prostate cancer; and FP-016 for the treatment of neurological diseases. Its new chemical entity pipeline products consist of FP-020 to treat sarcoidosis, idiopathic pulmonary fibrosis, and pulmonary emphysema; FP-025, a selective matrix metalloproteinase-12 inhibitor, which is in Phase II clinical trial for the treatment of asthma, chronic obstructive pulmonary diseases, and acute respiratory distress syndrome in COVID-19 patients; and FP-045, a selective aldehyde dehydrogenase (ALDH2) activator that completed Phase I clinical study for the treatment of fanconi anemia, as well as FP-040, an ALDH2 activator to treat central nervous system diseases. Foresee Pharmaceuticals Co., Ltd. was incorporated in 2013 and is based in Taipei, Taiwan.
截至 無 止,逸達 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中:無;董事會:無;股東權利:無;現金賠償:無。